CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 197 enrolled
Drug / intervention
SHR3680drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02691975
NCT02691975Phase 2Unknown
CompareCT.gov

A Phase I/II, Open-Label, Dose-Escalation and -Expansion, Safety, Pharmacokinetics and Efficacy Study of SHR3680 in Patients With Metastatic Castration-Resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.·interventional·Posted Feb 25, 2016·Updated May 13, 2020

In Brief

A Phase 2 clinical trial evaluating SHR3680 for Hormone Refractory Prostate Cancer and Metastatic Prostate Carcinoma. Targeting 197 participants across 12 sites.

Detailed Summary

This study evaluates the tolerability, safety, pharmacokinetics and efficacy of SHR3680 in patients with metastatic castration-resistant prostate cancer (mCPRC). All participants will receive SHR3680.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
20162017201820192020202120222023202420252026
First PostedFeb 25, 2016
Enrollment StartApr 12, 2016
Primary CompletionDec 1, 2020
Study CompletionJun 1, 2021
TodayJul 1, 2026
Enrollment to primary: 4.6 yearsPosted 10.3 years ago

Interventions

SHR3680drug

SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.